LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission

The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Abbott IP chief: ‘Firms without AI policies scare me’

5 March 2026 The healthcare company’s chief IP counsel is researching how law firms and patent attorneys are using AI tools to inform its own guidelines for external legal providers.

Americas

Moderna inks billion-dollar deal to settle long-running Spikevax dispute

5 March 2026 Moderna settles, agreeing to part with up to $2.25 billion to avoid a trial and secure a licence to continue using the platform underpinning its COVID-19 vaccine.

Careers

DWT recruits first-chair trial litigator as latest hire in IP expansion

4 March 2026 As the firm expands its IP offering, “an unusually versatile lawyer” with chemical, biologics, and medical device spaces expertise joins the New York office.

More features

Nomination call: Influential Women in IP list closes ahead of International Women’s Day

Abbott IP chief: ‘Firms without AI policies scare me’

Moderna inks billion-dollar deal to settle long-running Spikevax dispute

DWT recruits first-chair trial litigator as latest hire in IP expansion

FisherBroyles opens San Diego office

To cite or not to cite: How can we avoid misuse of AI in court?

Gowling WLG brings in transactions expert with UK and US experience

LSPN Awards 2026 finalists revealed

LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission

More on this story

Editor's picks

Editor's picks

More features